The incidence of factor VIII inhibitors in patients with severe hemophilia A

  • Leon W. Hoyer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


Inhibitor development is a serious complication of hemophilia A treatment. Although studies of inhibitor prevalence had been published earlier,1–3 the possibility that there is increased risk of inhibitor formation with different Factor VIII (F.VIII)-containing products was first raised when heat-treated concentrates were introduced. However, this concern was quickly dropped when it was apparent that heat treatment was necessary to inactivate HIV. As a result, no systematic study during the 1980s directly compared heat treated and non-heat treated F.VIII concentrates.


Factor VIII Recombinant Factor VIII Severe Hemophilia Inhibitor Formation Inhibitor Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C.K. Kasper. Incidence and course of inhibitors among patients with classic hemophilia, Thromb.etDiath.Haem.30:263 (1973).Google Scholar
  2. 2.
    H.S. Strauss. Acquired circulating anticoagulants in hemophilia A, N. Engl J. Med.281:866 (1969).PubMedCrossRefGoogle Scholar
  3. 3.
    C.W. McMillan, S.S. Shapiro, D. Whitehurst, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A:A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors, Blood71:344 (1988).PubMedGoogle Scholar
  4. 5.
    B.A. Bell, E.M. Kurczynski and G. Bergman. Inhibitors to monoclonal antibody purified factor VIII, Lancet336:638 (1990).PubMedCrossRefGoogle Scholar
  5. 5.
    CM. Kessler and K. Sachse. Factor VIILC inhibitor associated with monoclonal- 44 antibody purified FVIII concentrate, Lancet335:1403 (1990).PubMedCrossRefGoogle Scholar
  6. 6.
    J.E. Addiego, Jr., E.D. Gomperts, S.-L. Liu, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography, Thromb.Haem.67:19 (1992).Google Scholar
  7. 7.
    J.M. Lusher, P.M. Salzman and Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to Factor VIIIC concentrates, SeminHematol 27:1 (1990).Google Scholar
  8. 8.
    K. Peerlinck, J. Arnout, J.G. Gilles, J.M. Saint-Remy and J. Vermylen. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate, ThrombHaem. 69:115 (1993).Google Scholar
  9. 9.
    F.R. Rosendaal, H.K. Nieuwenhuis, H.M. van den Berg, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands, Blood8:2180 (1993).Google Scholar
  10. 10.
    R.S. Schwartz, CF. Abildgaard, L.M. Aledort, et al. Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A, N. Engl J.Med.323:1800 (1990).PubMedCrossRefGoogle Scholar
  11. 11.
    G.C. White, C.W McMillan, H.S. Kingdon and C.B. Shoemaker. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia, N. Engl J. Med.320:166 (1989).PubMedCrossRefGoogle Scholar
  12. 12.
    G.L. Bray. Current status of clinical studies of recombinant factor VIII (Recombinate®) in patients with hemophilia A, Trans.Med.Rev.VI:252 (1992).CrossRefGoogle Scholar
  13. 13.
    E.G.D. Tuddenham, D.N. Cooper, J. Gitschier, et al. Haemophilia A:database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, Nucl. Acids Res.19:4821 (1991).PubMedCrossRefGoogle Scholar
  14. 14.
    R. Pozzatti, J. Vogel and G. Jay. The human lymphotropic T virus type I taxgene can cooperate with the RAS oncogene to induce neoplastic transformation of cells, Mol. Cell. Biol.10:413 (1990).PubMedGoogle Scholar
  15. 15.
    L.E. Lippert, L.M. Fisher and L.B. Schook. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A, Thromb.Haem. 64:564 (1990).Google Scholar
  16. 16.
    A.M. Aly, L.M. Aledort, T.D. Lee and L.W. Hoyer. Histocompatibility antigen patterns in hemophilic patients with factor VIII antibodies, BrJ.Haematol76:238 (1990).CrossRefGoogle Scholar
  17. 17.
    D. Frommel, J.P. Allain, E. Saint-Paul, et al. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody, Thromb.Haem.46:687 (1981).Google Scholar
  18. 18.
    European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins, ScandJ. Haemat.23:64 (1979).Google Scholar
  19. 19.
    K. Peerlinck, F.R. Rosendaal and J. Vermylen. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood81:3332 (1993).PubMedGoogle Scholar
  20. 20.
    R. Schwaab, M. Ludwig, J. Oldenburg, et al. Identical point mutations in the factor VIII gene that have different clinical manifestations of hemophilia A, Am.J.Hum.Genet.47:743 (1990).PubMedGoogle Scholar
  21. 21.
    E.L. Kaplan and P. Meier. Nonparametric estimation from incomplete observations, J.Am.Statist.Assn.53:457 (1958).CrossRefGoogle Scholar
  22. 22.
    M.L. Lee, S. Liu-Maruya, S. Courter and E. Gomperts. Determining inhibitor-development risk in previously untreated hemophilia A patients treated (PUPs) with recombinant factor VIII (recombinate™), Blood80:49la (1992).Google Scholar
  23. 23.
    J. Addiego, C. Kasper, C. Abildgaard, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII, Lancet342:462 (1993).PubMedCrossRefGoogle Scholar
  24. 24.
    S. Ehrenforth, W. Kreuz, I. Scharrer, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet339:594 (1992).PubMedCrossRefGoogle Scholar
  25. 25.
    V. Rasi and E. Ikkala. Haemophiliacs with factor VIII inhibitors in Finland prevalence, incidence and outcome, BrJ.Haematol.76:369 (1990).CrossRefGoogle Scholar
  26. 26.
    R. De Biasi, A. Rocino, M.L. Papa and E. Salerno. Incidence of inhibitor development in hemophilia A patients, Thromb.Haem.69:1103 (1993).Google Scholar
  27. 27.
    G.L. Bray, E.D. Gomperts, S. Courter, et al. A multi-center study of recombinant factor VIII (Recombinate):Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A, Blood(1993).Google Scholar
  28. 28.
    J.M. Lusher, S. Arkin, C.F. Abildgaard, R.S. Schwartz and Kogenate. Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A, N.EnglJ.Meda.328:453 (1993).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Leon W. Hoyer
    • 1
  1. 1.Holland LaboratoryAmerican Red CrossRockvilleUSA

Personalised recommendations